1. Cazzola, M . Myelodysplastic syndromes. N Engl J Med 2020; 383: 1358–1374.
Google Scholar | Crossref | Medline2. Fenaux, P, Mufti, GJ, Hellstrom-Lindberg, E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223–232.
Google Scholar | Crossref | Medline | ISI3. Kantarjian, H, Issa, JP, Rosenfeld, CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794–1803.
Google Scholar | Crossref | Medline | ISI4. List, A, Dewald, G, Bennett, J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456–1465.
Google Scholar | Crossref | Medline | ISI5. Fenaux, P, Platzbecker, U, Mufti, GJ, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med 2020; 382: 140–151.
Google Scholar | Crossref | Medline6. de Witte, T, Bowen, D, Robin, M, et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood 2017; 129: 1753–1762.
Google Scholar | Crossref | Medline7. Cutler, CS, Lee, SJ, Greenberg, P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004; 104: 579–585.
Google Scholar | Crossref | Medline | ISI8. Lim, Z, Brand, R, Martino, R, et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol 2010; 28: 405–411.
Google Scholar | Crossref | Medline | ISI9. McSweeney, PA, Niederwieser, D, Shizuru, JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390–3400.
Google Scholar | Crossref | Medline | ISI10. Sayer, HG, Kroger, M, Beyer, J, et al. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant 2003; 31: 1089–1095.
Google Scholar | Crossref | Medline | ISI11. Ringden, O, Labopin, M, Ehninger, G, et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol 2009; 27: 4570–4577.
Google Scholar | Crossref | Medline | ISI12. Oudin, C, Chevallier, P, Furst, S, et al. Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies. Haematologica 2014; 99: 1762–1768.
Google Scholar | Crossref | Medline13. Schroeder, T, Rachlis, E, Bug, G, et al. Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions – a retrospective multicenter analysis from the German Cooperative Transplant Study Group. Biol Blood Marrow Transplant 2015; 21: 653–660.
Google Scholar | Crossref | Medline14. Yeung, CCS, Gerds, AT, Fang, M, et al. Relapse after allogeneic hematopoietic cell transplantation for myelodysplastic syndromes: analysis of late relapse using comparative karyotype and chromosome genome array testing. Biol Blood Marrow Transplant 2015; 21: 1565–1575.
Google Scholar | Crossref | Medline15. Schmid, C, de Wreede, LC, van Biezen, A, et al. Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation. Haematologica 2018; 103: 237–245.
Google Scholar | Medline16. Krishnamurthy, P, Potter, VT, Barber, LD, et al. Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant 2013; 19: 562–568.
Google Scholar | Crossref | Medline17. Schroeder, T, Czibere, A, Platzbecker, U, et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia 2013; 27: 1229–1235.
Google Scholar | Crossref | Medline18. Craddock, C, Labopin, M, Robin, M, et al. Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica 2016; 101: 879–883.
Google Scholar | Crossref | Medline19. Guieze, R, Damaj, G, Pereira, B, et al. Management of myelodysplastic syndrome relapsing after allogeneic hematopoietic stem cell transplantation: a study by the French Society of Bone Marrow Transplantation and Cell Therapies. Biol Blood Marrow Transplant 2016; 22: 240–247.
Google Scholar | Crossref | Medline20. Bishop, MR, Alyea, EP, Cairo, MS, et al. National Cancer Institute’s First International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: summary and recommendations from the organizing committee. Biol Blood Marrow Transplant 2011; 17: 443–454.
Google Scholar | Crossref | Medline21. de Lima, M, Porter, DL, Battiwalla, M, et al. Proceedings from the National Cancer Institute’s Second International Workshop on the biology, prevention, and treatment of relapse after hematopoietic stem cell transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation. Biol Blood Marrow Transplant 2014; 20: 4–13.
Google Scholar | Medline22. Bishop, MR, Alyea, EP, Cairo, MS, et al. Introduction to the reports from the National Cancer Institute First International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2010; 16: 563–564.
Google Scholar | Crossref | Medline23. Drobyski, WR, Keever, CA, Roth, MS, et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 1993; 82: 2310–2318.
Google Scholar | Crossref | Medline | ISI24. Mackinnon, S, Papadopoulos, EB, Carabasi, MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261–1268.
Google Scholar | Crossref | Medline | ISI25. Roddie, C, Peggs, KS. Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation. Expert Opin Biol Ther 2011; 11: 473–487.
Google Scholar | Crossref | Medline26. Enhancing the quality and transparency of health research , https://www.equator-network.org/
Google Scholar27. Arber, DA, Orazi, A, Hasserjian, R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391–2405.
Google Scholar | Crossref | Medline | ISI28. Di Grazia, C, Pozzi, S, Geroldi, S, et al. Wilms tumor 1 expression and pre-emptive immunotherapy in patients with acute myeloid leukemia undergoing an allogeneic hemopoietic stem cell transplantation. Biol Blood Marrow Transplant 2016; 22: 1242–1246.
Google Scholar | Crossref | Medline29. Rautenberg, C, Bergmann, A, Pechtel, S, et al. Wilm’s tumor 1-guided preemptive treatment with hypomethylating agents for molecular relapse of AML and MDS after allogeneic transplantation. Bone Marrow Transplant 2021; 56: 442–450.
Google Scholar | Crossref | Medline30. Platzbecker, U, Wermke, M, Radke, J, et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 2012; 26: 381–389.
Google Scholar | Crossref | Medline31. Bornhauser, M, Oelschlaegel, U, Platzbecker, U, et al. Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation. Haematologica 2009; 94: 1613–1617.
Google Scholar | Crossref | Medline32. Thiede, C, Bornhauser, M, Ehninger, G. Strategies and clinical implications of chimerism diagnostics after allogeneic hematopoietic stem cell transplantation. Acta Haematol 2004; 112: 16–23.
Google Scholar | Crossref | Medline33. Nollet, F, Billiet, J, Selleslag, D, et al. Standardisation of multiplex fluorescent short tandem repeat analysis for chimerism testing. Bone Marrow Transplant 2001; 28: 511–518.
Google Scholar | Crossref | Medline | ISI34. Bader, P, Niethammer, D, Willasch, A, et al. How and when should we monitor chimerism after allogeneic stem cell transplantation? Bone Marrow Transplant 2005; 35: 107–119.
Google Scholar | Crossref | Medline35. Cilloni, D, Renneville, A, Hermitte, F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol 2009; 27: 5195–5201.
Google Scholar | Crossref | Medline36. Yoon, JH, Jeon, YW, Yahng, SA, et al. Wilms tumor gene 1 expression as a predictive marker for relapse and survival after hematopoietic stem cell transplantation for myelodysplastic syndromes. Biol Blood Marrow Transplant 2015; 21: 460–467.
Google Scholar | Crossref | Medline37. Cheson, BD, Greenberg, PL, Bennett, JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108: 419–425.
Google Scholar | Crossref | Medline | ISI38. Dominik, LD, Selleslag, MD, Friedel, Nollet, et al. Efficacy of donor lymphocyte infusions in myelodysplastic syndromes relapsing after allogeneic stem cell transplantation: importance of karyotype. Blood 2004; 104: 1450.
Google Scholar | Crossref | Medline39. Della Porta, MG, Alessandrino, EP, Bacigalupo, A, et al. Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. Blood 2014; 123: 2333–2342.
Google Scholar | Crossref | Medline40. Shaffer, BC, Ahn, KW, Hu, ZH, et al. Scoring system prognostic of outcome in patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome. J Clin Oncol 2016; 34: 1864–1871.
Google Scholar | Crossref | Medline41. Gooptu, M, Koreth, J. A post-transplant optimized transplant-specific risk score in myelodysplastic syndromes. Haematologica 2019; 104: 859–861.
Google Scholar | Crossref | Medline42. Yahng, SA, Jeon, YW, Yoon, JH, et al. Dynamic prognostic value of the revised international prognostic scoring system following pretransplant hypomethylating treatment in myelodysplastic syndrome. Bone Marrow Transplant 2017; 52: 522–531.
Google Scholar | Crossref | Medline43. Schuurhuis, GJ, Heuser, M, Freeman, S, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 2018; 131: 1275–1291.
Google Scholar | Crossref | Medline44. Shapiro, RM, Kim, DDH. Next-generation sequencing-based minimal residual disease monitoring in patients receiving allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia or myelodysplastic syndrome. Curr Opin Hematol 2018; 25: 425–432.
Google Scholar | Crossref | Medline45. Thol, F, Gabdoulline, R, Liebich, A, et al. Measurable residual disease monitoring by NG